Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
100.00    -3.20 (-3.10%)
Bid:
100.40
Ask:
102.00
Spread: 1.60 (1.594%)
Market Cap: £163.94m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

8 Nov 2012 07:00

RNS Number : 6049Q
Yule Catto & Co PLC
08 November 2012
 



YULE CATTO & CO PLC

 

INTERIM MANAGEMENT STATEMENT

 

Continued resilient performance; Intention to change Group name

 

Yule Catto & Co plc ("Yule Catto" or "the Group") today issues its interim management statement for the period 1 July to 8 November 2012. The Group also announces its intention to change its name to Synthomer plc.

 

Trading

 

The Group has continued to perform in line with the Board's expectations since the last update provided at the interim results in August, despite the challenging macro-economic conditions, particularly in Europe.

 

In Europe and North America, profit to date remains well ahead of prior year. This has been achieved notwithstanding year to date volumes down 10%, and an adverse translation impact of £4.5 million in the first nine months of the year due to the weaker euro. This performance reflects the continued benefits of good margin management and synergy delivery which the Group has achieved during the period. Demand remains subdued with construction related areas continuing to be particularly affected. 

 

In Asia and ROW, the non-nitrile businesses continued the positive momentum achieved in the first half. Our Nitrile business is trading in line with the guidance provided at the interim results.

 

We continue to make strong progress with synergy delivery from the PolymerLatex acquisition, and remain firmly on track to realise £19 million of synergies in the current year, a year on year improvement of £16 million. The Group continues to expect to deliver the total £25 million of targeted annual synergies by March 2013. 

 

The Group's financial position remains robust with net debt at the end of September at £160 million, down from £174 million at the half year.

 

Outlook

 

The Board's expectations remain unchanged from those stated at the half year. Full year underlying profit before tax is expected to be ahead of 2011 pro-forma of £96 million.

 

Intention to change Group name to Synthomer plc

 

Over the last 5 years the Group has been transformed from a small, diversified chemical business, of which Yule Catto was the holding company, to a much larger, focussed speciality polymer business. The Group trades under the name Synthomer across the majority of its business, and the Board has therefore decided that now is an appropriate time to reflect this in the Group's name.

 

The Group will convene an Extraordinary General Meeting in on December 4 where shareholders will be asked to approve this change. If shareholders agree to this proposal, the Group's name will be changed to Synthomer plc before the year end. A circular to this effect will be distributed to shareholders today.

 

Commenting Adrian Whitfield, Group Chief Executive, said:

 

"We are pleased to have delivered a resilient performance in difficult market conditions. The Group's strong portfolio of products and leading market positions provide an excellent platform for growth and we remain confident of continuing to deliver value for our shareholders."

 

Enquiries:

 

Adrian Whitfield, Group Chief Executive

Charles Armitstead / Rosie Oddy

David Blackwood, Group Finance Director

Pendomer Communications

Tel: 01279 442791

Tel: 020 3603 5220

 

 

The company will host a conference call for analysts at 8.00am today. Please contact Pendomer Communications on 020 3603 5220 for dial in details.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSLLFFALLLDIIF
Date   Source Headline
4th Sep 20203:15 pmRNSDirector Declaration
6th Aug 20207:00 amRNSInterim Results for six months ended 30 June 2020
27th Jul 202010:00 amRNSPost Stabilisation Notice
16th Jul 20207:00 amRNSAppointment of Non-Executive Director
8th Jul 20204:16 pmRNSHolding(s) in Company
8th Jul 20204:14 pmRNSHolding(s) in Company
19th Jun 20207:00 amRNSSynthomer announces the pricing of senior notes
16th Jun 202011:54 amRNSPre Stabilisation Notice
16th Jun 202010:11 amRNSQ2 trading update
11th May 20205:21 pmRNSHolding(s) in Company
11th May 20209:03 amRNSDirector/PDMR Shareholding
11th May 20209:02 amRNSDirector/PDMR Shareholding
11th May 20208:59 amRNSDirector/PDMR Shareholding
11th May 20208:58 amRNSDirector/PDMR Shareholding
29th Apr 20203:17 pmRNSResult of AGM
29th Apr 20207:00 amRNSQ1 Trading and COVID-19 Update
1st Apr 20202:44 pmRNSCompletion of OMNOVA acquisition
1st Apr 20207:00 amRNSAnnual Financial Report
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:00 amRNSAppointment of Deputy Chair and Chair-elect
30th Mar 20207:00 amRNSDirector/PDMR Shareholding
26th Mar 202010:17 amRNSEuropean Commission clearance for OMNOVA
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
16th Mar 20209:50 amRNSDirector/PDMR Shareholding
13th Mar 20205:29 pmRNSDirector/PDMR Shareholding
9th Mar 20202:45 pmRNSHolding(s) in Company
5th Mar 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019
31st Jan 20209:36 amRNSDirector Declaration
15th Jan 20202:21 pmRNSAcquisition of OMNOVA receives EC clearance
6th Dec 20197:00 amRNSAppointment of Broker
13th Nov 20192:53 pmRNSDirector/PDMR Shareholding
11th Nov 20197:00 amRNSDirector Declaration
25th Oct 20197:00 amRNSQ3 Trading Update
22nd Oct 20197:00 amRNSAGM Statement
11th Oct 20197:00 amRNSOmnova shareholders approval
14th Aug 20193:25 pmRNSHolding(s) in Company
13th Aug 201912:33 pmRNSDirector/PDMR Shareholding
6th Aug 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
2nd Aug 201910:29 amRNSHolding(s) in Company
1st Aug 20199:05 amRNSHolding(s) in Company
31st Jul 201910:51 amRNSResults of Extraordinary General Meeting
30th Jul 20191:07 pmRNSDirector/PDMR Shareholding
30th Jul 20191:03 pmRNSDirector/PDMR Shareholding
30th Jul 20191:02 pmRNSDirector/PDMR Shareholding
30th Jul 20191:01 pmRNSDirector/PDMR Shareholding
30th Jul 201912:59 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:55 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.